Penetrance describes how often a genetic variant actually produces its expected effect in people who carry it. If every single person with a particular mutation develops the associated condition, that mutation has complete (or full) penetrance. If only some carriers develop the condition while others remain healthy, the mutation has incomplete penetrance. The concept matters enormously in medicine and genetic counseling because carrying a disease-linked variant does not always mean you will get the disease, and the gap between “having the gene” and “showing the trait” turns out to be influenced by a surprisingly wide range of factors.
The Basic Idea and Why It Is Not as Simple as It Sounds
At its core, penetrance is a binary measure applied across a group: for any individual carrier, the variant either produced the expected condition or it did not. A review in Frontiers in Genetics draws a useful distinction between penetrance and a related concept called variable expressivity. Penetrance asks whether the condition shows up at all, while expressivity asks how severe or varied the symptoms are when it does show up. Two people with the same mutation might both develop the condition (same penetrance) but one could have mild symptoms and the other severe ones (different expressivity).1PubMed Central. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts These are distinct phenomena, though in conversation they often get tangled together.
Penetrance is usually expressed as a percentage. If 80 out of 100 people carrying a specific variant develop the associated disease, the penetrance for that variant is 80%. But that number is not fixed in stone. It depends heavily on who you study, how long you follow them, and what other factors you account for. This is where the concept starts to get genuinely interesting.
Why Penetrance Estimates Shift Depending on Who You Study
One of the biggest lessons from large-scale genomic projects is that penetrance estimates gathered from families with strong disease histories tend to be higher than estimates gathered from the general population. The reason is straightforward: if you study a gene by looking at families where the disease keeps appearing, you are selecting for the very families where the variant happens to be doing its worst. You miss the families where someone carries the same variant but stays healthy and never ends up in a genetics clinic.
A large study that sequenced the genomes of more than 72,000 people from the UK Biobank and a New York health system (BioMe) found that many variants listed as disease-causing in clinical databases were carried by people who showed no signs of the corresponding condition.2JAMA. Population-Based Penetrance of Deleterious Clinical Variants This does not mean the variants are harmless. It means the real-world penetrance, measured in an unselected population, is often lower than the numbers derived from family studies. The practical takeaway: a penetrance figure you see quoted for a gene may overstate your personal risk if you learned about it through population screening rather than because your family has a history of the disease.
Research on high-penetrance cancer genes illustrates this pattern. For BRCA1 and BRCA2, the mutations most strongly linked to breast and ovarian cancer, penetrance estimates from family studies have historically been higher than what population-based sequencing suggests. One analysis noted that for women with a family history, breast cancer penetrance for these genes was estimated around 71%, compared with roughly 50% for a broader population sample.3JNCI: Journal of the National Cancer Institute. Population Testing for High Penetrance Genes: Are We There Yet? Similar patterns have been reported for TP53 and DICER1 mutations: population-based sequencing reveals more carriers than expected, many of whom have no disease, suggesting that published penetrance numbers may be inflated for the general population.
Age-Dependent Penetrance
Some genetic conditions do not appear at birth or in childhood. Instead, the risk of developing symptoms accumulates over a lifetime, and penetrance climbs with age. This is called age-dependent penetrance, and it is one of the reasons a young person carrying a disease-linked variant can appear perfectly healthy. They may simply not have reached the age at which the condition typically emerges.
Parkinson’s disease offers a clear example. A meta-analysis of Parkinson’s-linked mutations concluded that their penetrance is age-dependent and can be either increased or decreased by modifier genes and environmental factors across different populations.4PubMed. Disease penetrance of late-onset parkinsonism: a meta-analysis A person who carries one of these mutations at age 30 has a much lower chance of having developed symptoms than the same person at age 70.
The C9orf72 repeat expansion, linked to both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), provides an especially detailed picture. Researchers found that the median age at symptom onset among carriers was 58 years, and penetrance was nearly complete (about 99.5%) by age 83. More than half of neurologically normal carriers in the study were younger than the median onset age, which explains why they had not yet shown symptoms. The study also found that male carriers tended to develop disease about two years earlier than female carriers, and the type of onset (spinal vs. bulbar in ALS) influenced the age pattern as well.1PubMed Central. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts5Scientific Reports. Age-related penetrance of the C9orf72 repeat expansion
Animal models have helped explain the mechanics behind age-dependent penetrance. In a transgenic mouse model of familial ALS, researchers found that the gradual accumulation of damage in specific nerve cell populations over time was responsible for the age-dependent emergence of motor neuron disease.6Molecular and Cellular Neuroscience. Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis In other words, it was not that the gene suddenly “turned on” at a certain age. The damage was building all along, and the threshold for visible symptoms simply had not been crossed yet. This slow-burn model likely applies to many late-onset human conditions as well.
How Your Other Genes Change the Odds
A single mutation does not operate in isolation. It sits inside a genome containing thousands of other variants, and the combined effect of those background variants can push penetrance up or down substantially. Researchers have quantified this using polygenic scores, which capture the aggregate influence of many common genetic variants across the genome.
A study published in Nature Communications examined carriers of well-known disease-causing variants for three conditions the CDC considers high-priority for genomic screening: coronary artery disease, breast cancer, and colon cancer. Among people carrying the same type of high-risk variant, the probability of developing disease by age 75 ranged dramatically depending on polygenic background. For coronary artery disease, estimates ranged from 17% to 78%. For breast cancer, 13% to 76%. For colon cancer, 11% to 80%.7PubMed Central. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions Those are enormous ranges. Two people carrying the exact same “high-risk” variant could have wildly different actual risk depending on the rest of their genome.
This effect extends beyond cancer and heart disease. A study of autosomal dominant polycystic kidney disease (ADPKD) found a sharp gradient in chronic kidney disease risk among carriers of qualifying variants, depending on their polygenic risk score. Carriers in the lowest third of polygenic risk had about a threefold increase in kidney disease risk, while those in the highest third had more than a fiftyfold increase.8PubMed Central. Polygenic risk affects the penetrance of monogenic kidney disease The monogenic variant mattered, but how much it mattered depended enormously on the genetic context surrounding it.
Sex, Environment, and Epigenetics
Beyond other genes, penetrance can be shaped by sex and by factors outside the genome entirely. The sex dependence of certain conditions has been documented for decades. A review in Human Genetics notes that the penetrance of some disease-causing variants is known to be both age-dependent and sex-dependent.9PubMed Central. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease BRCA1 mutations, for instance, primarily affect breast and ovarian tissue, so their penetrance for cancer differs sharply between men and women even though both can carry the variant.
Environmental factors also play a role, particularly for lower-penetrance variants. Women carrying the same BRCA1 mutation within the same family can show different degrees of disease expression, a pattern attributed in part to environmental triggers and gene-environment interactions.3JNCI: Journal of the National Cancer Institute. Population Testing for High Penetrance Genes: Are We There Yet? Rare, high-penetrance mutations can sometimes cause disease regardless of external exposures, but many common, lower-penetrance genes are thought to exert their effects primarily through interactions with the environment.
At the cellular level, penetrance can even be affected by random noise in gene expression. A study in yeast, published in PLoS Genetics, found that disrupting certain cellular processes caused dramatic increases in the randomness (noise) of gene expression without changing the average level of expression.10PubMed Central. Cell-to-Cell Stochastic Variation in Gene Expression Is a Complex Genetic Trait This matters because when gene expression is noisy, genetically identical cells can behave differently from one another. Scaled up, this kind of molecular randomness could help explain why two people (or even two cells in the same person) carrying the same variant end up with different outcomes. It is a reminder that biology is not a perfectly deterministic machine.
Mosaicism and Unusual Inheritance Patterns
Sometimes apparent “low penetrance” in a family turns out to have a different explanation entirely: the person transmitting the variant does not actually carry it in every cell of their body. This is called somatic mosaicism, and it can make a parent appear unaffected even though they pass a full copy of the variant to their child.
A case study involving PCDH19-related epilepsy illustrated this phenomenon. A mother who appeared healthy was transmitting a disease-causing mutation to her children. When researchers tested multiple tissues from the mother, they discovered she carried the mutant version of the gene in only some of her cells, not all of them. This mosaic state meant she never had enough affected cells to develop the condition herself, but she could still pass the fully mutant version to her offspring through her egg cells.11PubMed. Somatic mosaicism of PCDH19 mutation in a family with low-penetrance EFMR Without the tissue-level testing, clinicians might have attributed the mother’s healthy status to “incomplete penetrance” of the gene, when in reality the explanation was that her body was a patchwork of mutant and normal cells.
This is an important distinction for genetic counseling. True incomplete penetrance, where a person has the variant in every cell but still does not develop the condition, and mosaicism, where a person only has the variant in a fraction of their cells, can look identical from the outside. The difference matters for estimating recurrence risk in a family and for deciding what kind of surveillance a carrier needs.
What Incomplete Penetrance Means for Genetic Testing
The rise of consumer and clinical genetic testing has made penetrance a practical concern for millions of people, not just researchers. When you receive a genetic test result saying you carry a variant “associated with” a condition, penetrance is the number that tells you how worried to be. And as the evidence shows, that number is rarely 100%.
Cystic fibrosis offers a well-known example of the counseling challenge. The R117H variant in the CFTR gene can produce anything from full-blown cystic fibrosis to no symptoms at all. This wide range makes genetic counseling difficult, especially in the context of newborn screening, where the variant’s high frequency introduces diagnostic dilemmas. Some infants flagged by screening will develop significant lung disease; others will remain essentially healthy throughout their lives.12Journal of Medical Genetics. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening
The growing use of genomic sequencing in research has also brought “secondary findings” to the forefront. These are disease-associated variants discovered incidentally when someone’s genome is sequenced for a different purpose. A study examining secondary findings in a research cohort emphasized that clinicians need to clearly communicate the concepts of variable penetrance and expressivity to people who test positive, particularly those with no symptoms. Without careful counseling, a finding of reduced penetrance can either cause unnecessary alarm or, conversely, false reassurance.13PubMed. Secondary Findings in a Research Cohort: Spectrum and the Indian Perspective
The challenge is compounded by the fact that penetrance estimates are population-level statistics, not individual predictions. Telling someone they carry a variant with 60% penetrance does not mean their personal risk is 60%. Their actual risk depends on their polygenic background, sex, age, environmental exposures, and potentially factors we have not yet identified. Genetic counselors walk a difficult line between communicating the statistical reality and helping individuals make personal decisions about surveillance, prevention, and family planning.
Evolutionary Pressures on Penetrance
If a mutation causes serious disease, you might expect natural selection to weed it out over generations. Yet many disease-associated variants persist at surprisingly high frequencies in human populations. Incomplete penetrance is part of the explanation: if a variant only causes disease in a fraction of carriers, selection pressure against it is weaker than it would be against a fully penetrant variant.
An intriguing study of BRCA1 mutation carriers who remained cancer-free explored whether common genetic variants elsewhere in the genome might have been naturally selected to counteract the cancer-promoting effects of the BRCA1 mutation. The researchers found evidence supporting this hypothesis, suggesting that in populations where BRCA1 mutations are common, protective variants at other genomic locations may have been favored by evolution, contributing to the incomplete penetrance observed in these families.14PubMed. Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers This dovetails neatly with the polygenic background research discussed earlier: the rest of the genome is not a passive bystander. It actively modulates whether a high-risk variant produces disease.
Penetrance Beyond Human Medicine
Incomplete penetrance is not unique to humans. It shows up across the biological world, from livestock to crops, and understanding it has practical consequences for breeding programs and agriculture.
In cattle, researchers studying a form of gonadal underdevelopment found that all affected animals carried two copies of an ectopic gene variant. But 17 unaffected animals also carried two copies, suggesting incomplete penetrance or the influence of additional unknown variants.15PLoS ONE. Ectopic KIT Copy Number Variation Underlies Impaired Migration of Primordial Germ Cells Associated with Gonadal Hypoplasia in Cattle (Bos taurus) For breeders trying to eliminate the condition from a herd, incomplete penetrance is a headache: you cannot simply remove all carriers based on genotype, because some carriers are perfectly healthy and productive.
In maize, incomplete penetrance complicates an entirely different kind of breeding goal. Researchers studying a gene involved in gynogenesis (a process used to create certain types of hybrid plants) found that the gene responsible was expressed in pollen with incomplete penetrance, meaning not every pollen grain carrying the variant actually triggered the desired outcome.16PubMed. A major locus expressed in the male gametophyte with incomplete penetrance is responsible for in situ gynogenesis in maize Crop geneticists working to improve breeding efficiency have to factor in these penetrance gaps just as human geneticists do when counseling patients.
These examples underscore that incomplete penetrance is not a quirk of human genetics or a failure of our diagnostic tools. It is a fundamental feature of how genomes interact with the rest of biology. Whether the organism is a person, a cow, or a corn plant, the path from a DNA variant to a visible trait is rarely a straight line. It is filtered through other genes, developmental timing, cellular noise, environmental conditions, and sometimes just chance. That complexity is what makes penetrance such a central concept in genetics, and why a single percentage attached to a variant never tells the whole story.